Cameron Turtle | BiotechTV

top of page

Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination than current therapies for IBD and rheumatology

CEO Cameron Turtle describes the improvements Spyre is making in its therapies. 2026 is going to be a data rich year for IBD. Coverage brought to you by

Company News

5 days ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

Learn more about Evaluate

bottom of page

Spyre Therapeutics is developing a basket of therapies (α4β7, TL1A, and IL-23) that are meant to have a greater half-life and work better in combination than current therapies for IBD and rheumatology

Follow BiotechTV

Sponsors

Sponsor Spotlight